BACKGROUND: MicroRNAs (miRNAs) are small non-coding genes which become dysregulated in cancer and may predict survival. The role of miRNAs in outcomes in cholangiocarcinoma (CC) has not been reported. METHODS: RNA was extracted from 32 resected CCs along with adjacent uninvolved bile duct epithelium. A total of 43 miRNAs were quantified using NanoString™. Clinicopathologic characteristics and outcomes were captured and compared. Overall survival curves were created using the Kaplan-Meier method; factors, including miRNA expression, were compared by log-rank, chi-squared or Cox regression analyses. RESULTS: Absolute expression of each miRNA was compared with overall survival after excluding perioperative deaths (n= 3). One upregulated (miR-151-3p; P= 0.003) and one downregulated (miR-126; P= 0.023) miRNA in resected CC relative to adjacent normal bile duct epithelium correlated with survival on univariate analysis. Clinical factors and these miRNAs were compared. Dysregulated miR-151-3p and miR-126, respectively, were the only factors that correlated with improved overall survival [41.5 months vs. 12.3 months (P= 0.002) and 21.9 months vs. 15.1 months (P= 0.02), respectively]. In eight patients, both miRNAs were dysregulated. In the remainder, only one or neither showed dysregulation. Concomitant dysregulation correlated with the best overall survival (58.7 months vs. 15.1 months; P < 0.000; n= 8); clinicopathologic factors in these groups were otherwise similar. CONCLUSIONS: In resected CC, the concomitant dysregulation of both miR-151-3p and miR-126 was the factor related to the greatest improvement in overall survival. Further analysis of the targets of these miRNAs may yield potential therapeutic targets or prognostic biomarkers.
BACKGROUND: MicroRNAs (miRNAs) are small non-coding genes which become dysregulated in cancer and may predict survival. The role of miRNAs in outcomes in cholangiocarcinoma (CC) has not been reported. METHODS: RNA was extracted from 32 resected CCs along with adjacent uninvolved bile duct epithelium. A total of 43 miRNAs were quantified using NanoString™. Clinicopathologic characteristics and outcomes were captured and compared. Overall survival curves were created using the Kaplan-Meier method; factors, including miRNA expression, were compared by log-rank, chi-squared or Cox regression analyses. RESULTS: Absolute expression of each miRNA was compared with overall survival after excluding perioperative deaths (n= 3). One upregulated (miR-151-3p; P= 0.003) and one downregulated (miR-126; P= 0.023) miRNA in resected CC relative to adjacent normal bile duct epithelium correlated with survival on univariate analysis. Clinical factors and these miRNAs were compared. Dysregulated miR-151-3p and miR-126, respectively, were the only factors that correlated with improved overall survival [41.5 months vs. 12.3 months (P= 0.002) and 21.9 months vs. 15.1 months (P= 0.02), respectively]. In eight patients, both miRNAs were dysregulated. In the remainder, only one or neither showed dysregulation. Concomitant dysregulation correlated with the best overall survival (58.7 months vs. 15.1 months; P < 0.000; n= 8); clinicopathologic factors in these groups were otherwise similar. CONCLUSIONS: In resected CC, the concomitant dysregulation of both miR-151-3p and miR-126 was the factor related to the greatest improvement in overall survival. Further analysis of the targets of these miRNAs may yield potential therapeutic targets or prognostic biomarkers.
Authors: Florin M Selaru; Alexandru V Olaru; Takatsugu Kan; Stefan David; Yulan Cheng; Yuriko Mori; Jian Yang; Bogdan Paun; Zhe Jin; Rachana Agarwal; James P Hamilton; John Abraham; Christos Georgiades; Hector Alvarez; Perumal Vivekanandan; Wayne Yu; Anirban Maitra; Michael Torbenson; Paul J Thuluvath; Gregory J Gores; Nicholas F LaRusso; Ralph Hruban; Stephen J Meltzer Journal: Hepatology Date: 2009-05 Impact factor: 17.425
Authors: M Crawford; E Brawner; K Batte; L Yu; M G Hunter; G A Otterson; G Nuovo; C B Marsh; S P Nana-Sinkam Journal: Biochem Biophys Res Commun Date: 2008-07-03 Impact factor: 3.575
Authors: Ioannis Hatzaras; Nathaniel George; Peter Muscarella; W Scott Melvin; E Christopher Ellison; Mark Bloomston Journal: Ann Surg Oncol Date: 2010-01-28 Impact factor: 5.344
Authors: Sergio A Gradilone; Steven P O'Hara; Tetyana V Masyuk; Maria Jose Lorenzo Pisarello; Nicholas F LaRusso Journal: Semin Liver Dis Date: 2015-01-29 Impact factor: 6.115
Authors: Alexander Baraniskin; Stefanie Nöpel-Dünnebacke; Brigitte Schumacher; Christian Gerges; Thilo Bracht; Barbara Sitek; Helmut E Meyer; Guido Gerken; Alexander Dechene; Jörg F Schlaak; Roland Schroers; Christian Pox; Wolff Schmiegel; Stephan A Hahn Journal: Dig Dis Sci Date: 2014-01-31 Impact factor: 3.199
Authors: Lucas Poleto Spinola; Gabriel F Vieira; Rafael Fernandes Ferreira; Maria C J Calastri; Graciele D Tenani; Franciana L Aguiar; Ilka F Santana Ferreira Boin; Larissa B E Da Costa; Maria Fernanda Chaim Correia; Eliane M Zanovelo; Daniele C B De Souza; Rita C Martins Alves Da Silva; Renato Ferreira Da Silva; Ana Margarida Coelho Abrantes; Maria Filomena R R Botelho; Jose Guilherme L R Tralhão; Doroteia R S Souza Journal: Asian Pac J Cancer Prev Date: 2021-02-01
Authors: Nicole Noren Hooten; Megan Fitzpatrick; William H Wood; Supriyo De; Ngozi Ejiogu; Yongqing Zhang; Julie A Mattison; Kevin G Becker; Alan B Zonderman; Michele K Evans Journal: Aging (Albany NY) Date: 2013-10 Impact factor: 5.682